Immunovant, Inc.
Current role
IMVT
Frank Torti
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Frank Torti
Earlier roles on record: Chairman at Arbutus Biopharma Corp (ABUS) until February 24, 2025. The proxy statement of Roivant Sciences Ltd. reports total compensation of $123,300,566 for Frank Torti in fiscal 2025, including a base salary of $725,000.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Immunovant, Inc. (IMVT)
Source not stated
Current -
Roivant Sciences Ltd. (ROIV)
Proxy statement
CurrentStart not stated–present
-
Start not stated–2025-02-24
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Immunovant, Inc.
Other people whose current roles at this company are on record from its filings.
- Eric Venker CEO
- Eric Venker, M.D. CEO, Board Member
- Eric Venker, M.D., Pharm.D. CEO
- Dr. Frank M. Torti Chairman
- Renee Barnett CFO
- Tiago Girao CFO
- Melanie Gloria COO
- Jay S. Stout CTO
- W. Bradford Middlekauff General Counsel
- Andrew Fromkin Board Member
Leadership on record at Roivant Sciences Ltd.
Other people whose current roles at this company are on record from its filings.
- Eric Venker CEO, COO
- Matthew Gline CEO, Board Member
- Richard Pulik CFO
- Jennifer Humes Chief Accounting Officer
- Daniel Gold Board Member
- Hiroshi Nomura Board Member
- Ilan Oren Board Member
- James C. Momtazee Board Member
- Keith Manchester Board Member
- Mayukh Sukhatme Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Roivant Sciences Ltd. (ROIV) | President and Vant Chair | $725,000 | $123,300,566 |
Recent activity
No call appearances or filed executive changes recorded yet.